Financial expert: Bayer boss expresses concerns about the product pipeline - poor investments as a reason

Financial expert: Bayer boss expresses concerns about the product pipeline - poor investments as a reason

According to a report by www.finanzen.net, Bayer boss Bill Anderson attributed the thin product pipeline in the pharmaceutical division after the sudden end of an important study to insufficient investments in the past. He said that Bayer had been underinvested in the years up to around 2018 and had not researched any new molecules. This has resulted in the product pipeline being thin compared to the expiring patents.

Analyzing the situation, it becomes clear that the sudden termination of the study of the drug Asundexian led to an 18 percent drop in the share price in one day. This illustrates the strong reaction of investors to the failed study. The expected peak sales of the drug are now also being lost, which has a significant financial impact on the company.

The Bayer boss's statement that research and development is on track sounds optimistic. However, it remains uncertain whether the current difficulties can be offset by the underinvested phase. The fact that Bayer is considering splitting up to find a strategy that better fits its current challenges is a clear sign of the difficulties the company is facing.

These developments have a direct impact on Bayer shares, which continue their downward trend at their lowest level since 2006. The annual loss is now 34.5 percent, which underlines the company's worrying situation. The possibility of a split has recently been raised as a possibility among investors, reflecting concerns about the company's future.

Overall, Bayer's current situation is characterized by uncertainty and significant financial impact, highlighting the company's urgent need to find a solution to its current problems.